LEUKERAN

LOE Approaching

chlorambucil

NDAORALTABLETPriority Review
Approved
Mar 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Alkylating Activity

Pharmacologic Class:

Alkylating Drug

Clinical Trials (5)

NCT04578613Phase 3Unknown

ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Started Jan 2021
218 enrolled
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
NCT04075292Phase 3Active Not Recruiting

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Started Jan 2020
155 enrolled
Untreated Chronic Lymphocytic Leukemia
NCT04059081Phase 2Unknown

A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Started Jul 2019
31 enrolled
Chronic Lymphocytic Leukemia
NCT03462719Phase 3Active Not Recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Started Apr 2018
211 enrolled
Leukemia, Lymphocytic, Chronic, B-Cell
NCT02612311Phase 3Terminated

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Started Nov 2015
603 enrolled
Chronic Lymphocytic Leukemia